This study is conducted in Asia. The aim of this observational study is to compare the clinical safety profile and effectiveness of NovoMix® 30 and Levemir™ for the treatment of diabetes in the Philippines.

Inclusion Criteria:

• Patients diagnosed with type 1 or type 2 diabetes mellitus
• Patients uncontrolled on oral antidiabetic drugs
• Insulin naïve patients or patients currently on human insulin

Exclusion Criteria:

• Subjects who are unlikely to comply with protocol requirements
• Subjects who are previously enrolled in NovoMix® 30 and Levemir™ study
• Subjects on NovoMix® 30 and Levemir™ therapy
• Subjects with hypersensitivity to NovoMix® 30 or to any of the excipients
• Subjects with hypersensitivity to Levemir™ or to any of the excipients
• Females of child bearing potential who are pregnant, breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures are required by local law or practice
• Contraindications and warnings specified in the current prescribing information

Any subject with diabetes mellitus who needs insulin treatment at the time of inclusion is eligible for the study, including newly diagnosed subjects who have never received insulin or an insulin analogue before